Japanese Preprint Calls For mRNA VaccinesTo Be Suspended Over Blood Bank Contamination Concerns
Authored by Naveen Athrappully via The Epoch Times (emphasis ours), Receiving blood transfusion from COVID-19-vaccinated individuals could pose a medical risk to unvaccinated recipients since numerous…#vaccinestobe #naveenathrappully #epochtimes #astrazeneca #fazlmosque #southfields #contrary #repeated #newzealand #davesidhu (Source: Reuters: Health)
Source: Reuters: Health - March 23, 2024 Category: Consumer Health News Source Type: news
3 Stagnating Blue-Chip Stocks Ready to Awaken and Soar
In my view, a sure-shot way of minting money from the markets is buying and holding with patience. Of course, the idea needs to be well-researched as a first step. An important point to note is that stocks can witness price or time correction. This column focuses on stagnating blue-chip stocks…#lockheedmartin #lmt #nato #lockheed #fcf #astrazeneca #occidentalpetroleum #oxy #opec #occidental (Source: Reuters: Health)
Source: Reuters: Health - March 20, 2024 Category: Consumer Health News Source Type: news
AstraZeneca to buy fusion for $2 billion
The deal gives AstraZeneca a foothold in the radiopharmaceutical drugs market, which has seen increasing investor interest since 2021 when data from Novartis' treatment showed that the drug extended survival for prostate cancer patients. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 19, 2024 Category: Pharmaceuticals Source Type: news
AstraZeneca bets $2B on Canada-Boston biotech
The upfront transaction is valued at around $2 billion, which is a 97% premium to the Canada-Boston biotech's closing market price of $10.64 on Monday before the deal was announced. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 19, 2024 Category: Pharmaceuticals Authors: Hannah Green Source Type: news
AstraZeneca to buy Canadian cancer specialist Fusion for $2.4bn
Britain ’s biggest drugmaker’s latest acquisition will help it to develop new radiotherapy treatmentsBusiness live – latest updatesBritain ’s biggest drugmaker, AstraZeneca, is to buy a Canadian cancer specialist focused on next-generation treatments for $2.4bn (£1.9bn), the latest in a string of acquisitions made to strengthen its portfolio of new medicines.The Anglo-Swedish company struck an agreement to acquire Fusion Pharmaceuticals, which is developing next-generation radioconjugates that offer an alternative to chemotherapy and radiotherapy. It has emerged as a new type of cancer treatment in recent years, a...
Source: Guardian Unlimited Science - March 19, 2024 Category: Science Authors: Julia Kollewe Tags: AstraZeneca Pharmaceuticals industry Mergers and acquisitions Cancer research Medical research Science Business UK news Source Type: news
AstraZeneca to Buy Fusion Pharma for Up to $2.4 Billion
(Source: Reuters: Health)
Source: Reuters: Health - March 19, 2024 Category: Consumer Health News Source Type: news
These Stocks Are Moving the Most Today
Nvidia shares fall after the semiconductor company unveils its highly anticipated Blackwell chip, while Fusion Pharmaceuticals surges after reaching a deal to be acquired by AstraZeneca.#nvidia #blackwell #astrazeneca (Source: Reuters: Health)
Source: Reuters: Health - March 19, 2024 Category: Consumer Health News Source Type: news
AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion
AstraZeneca is buying Fusion Pharmaceuticals for $2.4 billion as the London-listed group looks to build its presence in cutting-edge cancer treatments.#astrazeneca (Source: Reuters: Health)
Source: Reuters: Health - March 19, 2024 Category: Consumer Health News Source Type: news
AstraZeneca to Cap Out-of-pocket Inhaler Costs in US, Following Rival Boehringer's Move AstraZeneca to Cap Out-of-pocket Inhaler Costs in US, Following Rival Boehringer's Move
Drugmaker AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States from June, following a...Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 19, 2024 Category: Allergy & Immunology Tags: Pulmonary Medicine Source Type: news
AstraZeneca will cap inhaler costs at $35 per month
The cost-reduction strategy follows a similar move from Boehringer Ingelheim, a rival in the medical device sector. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - March 18, 2024 Category: Consumer Health News Authors: Aaron Gregg Source Type: news
AstraZeneca capping patients' monthly out-of-pocket expenses for inhaled medicines at $35
The AstraZeneca patient spending cap comes amid a U.S. Senate investigation into the pricing of inhaled medicines in the United States. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 18, 2024 Category: Pharmaceuticals Authors: John George Source Type: news
AstraZeneca Follows Rival Boehringer in Capping Out-of-pocket Costs for Inhalers AstraZeneca Follows Rival Boehringer in Capping Out-of-pocket Costs for Inhalers
Drugmaker AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, following a similar move by...Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 18, 2024 Category: Allergy & Immunology Tags: Pulmonary Medicine Source Type: news
AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolio
(Source: Reuters: Health)
Source: Reuters: Health - March 14, 2024 Category: Consumer Health News Source Type: news
AstraZeneca strikes $1 billion deal for rare-disease drug maker
AstraZeneca on Thursday struck a $1 billion deal to buy a maker of drug for rare diseases, further building out the capabilities it acquired in the 2021 deal for Alexion Pharmaceuticals. (Source: Reuters: Health)
Source: Reuters: Health - March 14, 2024 Category: Consumer Health News Source Type: news
